Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 07209326

Next Previous
Drug Profile

PF 07209326

Alternative Names: PF-07209326

Latest Information Update: 11 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Antianaemics
  • Mechanism of Action E-selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Sickle cell anaemia

Most Recent Events

  • 31 Jul 2023 PF 07209326 is still in phase I trials for Sickle cell anaemia (In volunteers) in USA (NCT04255875)
  • 31 Jul 2023 Pfizer completes a phase I trial for Sickle cell anaemia (In volunteers) in USA (SC) (NCT04255875)
  • 02 May 2023 Discontinued - Phase-I for Sickle cell anaemia (In volunteers) in USA (IV) (Pfizer pipeline, August 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top